What is the confirmed market size and growth trajectory for the veterinary surgical procedures market?
The market was valued at USD 51.2 billion in 2025 and is projected to grow at a CAGR of 7.5% to USD 98.16 billion by 2035. Companion animal surgery is dominant and fastest-growing by spend. Orthopaedic surgery generates the highest specialist procedure revenue. Cancer surgery is growing fastest by case volume. Minimally invasive laparoscopic and arthroscopic surgery is the fastest-growing technique. North America leads; Asia-Pacific grows fastest.

How does TPLO surgery define the companion animal orthopaedic market?
TPLO — tibial plateau levelling osteotomy, the surgical correction of canine cruciate ligament rupture — generates USD 4,000 to USD 7,000 per case at board-certified veterinary surgeon fees. With approximately 2.5 million cases annually in the U.S. alone, TPLO creates structural surgical volume that grows with the expanding canine population and the increasing veterinary diagnosis rate of cruciate rupture in active and overweight dogs.

How does IDEXX Telemedicine support veterinary surgical planning and outcomes?
IDEXX Telemedicine’s radiology, internal medicine, and cardiology consultation services directly support veterinary surgical planning — enabling primary care veterinarians to access specialist interpretation of radiographs, echocardiograms, and complication assessments remotely. Pre-surgical specialist consultation enables evaluation of anaesthetic risk, surgical approach suitability, and post-operative monitoring requirements before specialist referral.

What is driving minimally invasive veterinary surgery growth?
Laparoscopic and arthroscopic veterinary surgery is growing as specialist veterinarians trained in minimally invasive techniques expand availability, veterinary-specific laparoscopic systems develop, and pet owners prefer the faster recovery, reduced pain, and lower complication rates that minimally invasive approaches provide. Corporate specialist hospitals invest in capital equipment that general practices cannot justify.

How does Librela create a pharmaceutical complement to veterinary orthopaedic surgery?
Librela — anti-NGF monoclonal antibody for canine OA pain — functions as post-operative pain management for orthopaedic surgery patients (TPLO, hip replacement, FHO) rather than a surgical alternative for cruciate rupture, which requires surgical correction regardless of pain management. Librela’s monthly dosing post-operatively creates recurring pharmaceutical revenue above the one-time surgical procedure.

What drives veterinary oncology surgery as the fastest-growing companion animal surgical category?
Companion animal cancer surgery — tumour resection, mastectomy, splenectomy, hepatic mass excision — is growing fastest by case volume, driven by the IDEXX Cancer Dx Panel creating earlier oncology diagnosis that identifies surgically resectable tumours before clinical signs appear. Earlier detection increases the proportion of oncology patients who are surgical candidates, growing surgical case volume from the growing base of diagnosed companion animal cancer patients.